The best indicator for Edwards Lifesciences (EW)
We backtested 20 indicators across daily, weekly and hourly charts on real Edwards Lifesciences (EW) history. Here's what actually worked — risk-adjusted, out-of-sample, with costs.
CCI
On the daily chart, this is the strongest risk-adjusted edge we found for Edwards Lifesciences (EW) over ~26.1 years — trailing buy-and-hold by 2.3% CAGR.
The winner on each chart
Every indicator, ranked
Ranked by Sharpe (risk-adjusted return). Hypothetical, fees included.
| # | Indicator | TF | CAGR | Sharpe | Max DD | Win | Trades | vs B&H |
|---|---|---|---|---|---|---|---|---|
| 1 | CCI ✓ | Daily | 14.8% | 0.82 | -33.6% | 78.4% | 134 | -2.3% |
| 2 | Money Flow Index ✓ | Daily | 12.9% | 0.7 | -45.2% | 86.2% | 29 | -4.2% |
| 3 | WaveTrend (8/6/4) ✓ | Daily | 12.4% | 0.65 | -56.0% | 78.9% | 95 | -4.7% |
| 4 | Stochastic ✓ | Daily | 10.4% | 0.63 | -33.6% | 75.6% | 123 | -6.7% |
| 5 | Williams %R ✓ | Weekly | 8.6% | 0.61 | -29.6% | 83.3% | 36 | -9.3% |
| 6 | Stochastic ✓ | Weekly | 7.6% | 0.58 | -25.5% | 79.2% | 24 | -10.3% |
| 7 | Williams %R ✓ | Daily | 9.7% | 0.56 | -35.0% | 74.3% | 175 | -7.4% |
| 8 | Holy Grail Confluence ✓ | Daily | 8.3% | 0.55 | -40.1% | 83.8% | 37 | -8.9% |
| 9 | Bollinger Mean-Reversion ✓ | Daily | 7.8% | 0.53 | -38.3% | 78.4% | 102 | -9.4% |
| 10 | EMA 50/200 Cross ✓ | Daily | 9.7% | 0.49 | -60.5% | 60.0% | 15 | -7.4% |
| 11 | SMA 50/200 Cross ✓ | Daily | 9.0% | 0.48 | -56.4% | 55.6% | 18 | -8.1% |
| 12 | CCI ✓ | Weekly | 5.9% | 0.44 | -44.7% | 80.8% | 26 | -12.0% |
| 13 | MACD ✓ | Weekly | 6.5% | 0.41 | -48.0% | 57.1% | 56 | -11.4% |
| 14 | Donchian Midline ✓ | Weekly | 6.4% | 0.38 | -43.9% | 51.4% | 70 | -11.5% |
✓ = held up out-of-sample. Hypothetical, costs included. See methodology.
For Edwards Lifesciences (EW), CCI on the daily timeframe gave the best balance of return and risk in our test. It still trailed buy-and-hold on raw return — but remember: this is a hypothetical backtest of a standard rule, not a recommendation. Markets change. See the methodology and disclaimer.
More stock
Get the weekly edge report
The best-performing indicator per asset, what changed this week, and the honest caveats — straight to your inbox.